Stockscreener 앱 받기
37.26
1.11%
0.41
시간 외 거래:
37.25
-0.010
-0.03%
전일 마감가:
$36.85
열려 있는:
$36.85
하루 거래량:
1.75M
Relative Volume:
0.47
시가총액:
$16.11B
수익:
$2.31B
순이익/손실:
$1.66B
주가수익비율:
16.22
EPS:
2.297
순현금흐름:
$827.02M
1주 성능:
+0.68%
1개월 성능:
+4.17%
6개월 성능:
+16.33%
1년 성능:
+36.58%
1일 변동 폭
$36.85
$37.40
1주일 범위
$36.11
$37.69
52주 변동 폭
$24.05
$38.00
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.26 | 15.93B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
What the charts say about Royalty Pharma plc today2025 Biggest Moves & AI Driven Stock Reports - newser.com
Detecting support and resistance levels for Royalty Pharma plcQuarterly Earnings Summary & Daily Technical Forecast Reports - newser.com
Royalty Pharma plc (RPRX) Strikes $2B Partnership with Revolution Medicines - MSN
Can Royalty Pharma plc stock beat analyst upgradesJuly 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - newser.com
Weiss Ratings Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold (C+) - MarketBeat
Is Royalty Pharma plc (RPD) stock a buy during volatile marketsGap Down & Detailed Earnings Play Alerts - newser.com
Is Royalty Pharma plc reversing from oversold territoryTrend Reversal & Low Risk Entry Point Guides - newser.com
Using Python tools to backtest Royalty Pharma plc strategies2025 Technical Patterns & AI Driven Price Predictions - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next yearJuly 2025 Movers & Verified Chart Pattern Trade Signals - newser.com
Why retail investors pile into Royalty Pharma plc stockAnalyst Upgrade & Short-Term High Return Strategies - newser.com
Why Royalty Pharma plc (RPD) stock could rally strongly2025 Key Lessons & Fast Gain Stock Tips - newser.com
What indicators show strength in Royalty Pharma plcGap Down & Verified Momentum Stock Watchlist - newser.com
What’s the recovery path for long term holders of Royalty Pharma plcJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
What to Know Before Buying the Dip in SPEL Semiconductor LimitedTrend Following Strategies & Free Phenomenal Trading Returns - earlytimes.in
What Drawdown Risk Means for Long Term Holders of Innomet Advanced Materials LimitedCurrency Fluctuation Impact & Low Risk Trading Portfolio - earlytimes.in
Rehmann Capital Advisory Group Sells 8,893 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Does Royalty Pharma plc qualify in momentum factor screeningGap Down & Long-Term Investment Growth Plans - newser.com
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.21%
0.29%
자본화:
|
볼륨(24시간):